Jan 20, 2012
LONDON (AP) – A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.
The drug, Gilenya, was licensed last year in the European Union to treat patients with a severe type of multiple sclerosis.
The deaths raise concerns Gilenya could trigger heart problems after patients take their first dose, according to a statement issued Friday by the European Medicines Agency. The agency, which is now investigating the drug, said it isn’t clear if it caused the deaths.
One of the deaths was in the U.S., where a patient died within 24 hours of taking the first dose.
..Comments for each blog posting are always appreciated.
Please use the link found below, to leave comments..
.. All comments are moderated to reduce SPAM and bad language
.. All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
– Click to: REGISTER – For our MS weekly e-Newsletter
“Providing You with ‘MS Views and News’, IS What We Do”
Help us to educate $ DONATE NOW PLEASE $
“MS Views and News” is a 501©(3) Not-For-Profit organization
as recognized by the Internal Revenue Service
All contributions are tax deductible to the fullest extent allowed by law
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
